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Introduction
More than 300 million people of all ages suffer from depression, which is a major contributor to the overall global burden of disease (WHO, 2017) . Approximately one-third of depressed patients have a treatment-resistant form of depression after trialing typical antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). Moreover, these antidepressants have proven ineffective in the treatment of suicide ideation in patients with severe depression. Novel therapeutic agents are therefore required to meet these unmet needs. In recent decades, (R,S)-ketamine (Figure 1) has come to the attention of neuroscientists and psychiatrists worldwide because it produces robust antidepressant effects in patients with treatment-resistant depression (Duman, 2018;  J o u r n a l P r e -p r o o f 4 2012; Hoiseth et al., 2005) , resulting in its medical use in humans being terminated in 1965 (Morris and Wallach, 2014) .
In efforts to identify an alternative to PCP without the serious psychotomimetic side effects, but that retained the excellent anesthetic effects (Mion, 2017) , the original form of ketamine (CI-581) was synthesized as short half-life derivative of PCP by Parke-Davis (Figure 2) (Domino, 2010) . In 1964, Dr., Edward Domino and Dr. Guenter Corssen performed the first study of the anesthetic effects of CI-581 in healthy prisoners (Domino, 2010) . Shortly thereafter, in 1965, ketamine was confirmed to be an effective analgesic and anesthetic . In the first clinical study of ketamine among 130 patients who underwent surgical procedures it was reported to induce a unique state of altered consciousness, described as being disconnected (Corssen and Domino, 1966) . Ketamine was later approved in 1970 for anesthetic use by the US Food Drug Administration (FDA) (Figure 2) Mion, 2017; Stevenson, 2005) . However, due to its euphoric effects, ketamine became a popular recreational drug in the US and Europe in subsequent decades (Lankenau, 2016; Wolff, 2016) . Ketamine remains a commonly abused illicit drug worldwide (Liu et al., 2016b) .
Contemporaneous reports since the 1970s have shown that ketamine hydrochloride (Ketalar Ⓡ ) received much attention, with researchers exploring its pharmacokinetics and mechanism of anesthetic and analgesic action for therapeutic purposes (Li and Vlisides, 2016; Lodge and Mercier, 2015; Tyler et al., 2017) . As part of this history, it is worth noting that ketamine was shown to be an NMDAR antagonist in 1983 (Figure 2) (Anis et al., 1983) . Given ketamine's unique properties in pain relief and sedation (Gao et al., 2016) , ketamine was added to the WHOs essential medicines list as an intravenous anesthetic in 1985 (Figure 2) (Gowda et al., 2016; WHO, 2011) . Although it has now been used for more than 50 years, not only as an anesthetic and analgesic agent but also as a drug of abuse, its use remains limited due to its undesirable psychotomimetic effects.
J o u r n a l P r e -p r o o f
Antidepressant-like effects of (R,S)-ketamine and NMDAR antagonists in rodents
In 1975, (R,S)-ketamine was reported to show antidepressant-like effects in animal models. For example, it was associated with the reversal of tetrabenazine-induced ptosis in mice, reversal of reserpine-induced hypothermia in rats, enhancement of yohimbine toxicity in mice, and inhibition of oxotremorine-induced tremors in mice (Sofia and Harakal, 1975) . In these models, however, the antidepressant-like activity of ketamine was substantially less than that of imipramine (Sofia and Harakal, 1975) .
As already mentioned, ketamine was identified to be an NMDAR antagonist in 1983 (Figure 2) (Anis et al., 1983) . In 1990 it was reported that NMDAR antagonists like AP-7 and (+)-MK-801 had antidepressant-like effects in rodents (Trullas and Skolnick, 1990) . In a chronic mild stress model, (+)-MK-801 showed anti-anhedonia-like effects in rats (Papp and Moryl, 1993) . Several animal studies soon documented that NMDAR antagonists, such as MK-801, CGP 37849, and eliprodil, may have the antidepressant-like effects in animal model of depression (Autry et al., 2011; Layer et al., 1995; Maj et al., 1992; Meloni et al., 1993; Papp and Moryl, 1994; Petrie et al., 2000; Skolnick et al., 1996; Wedzony et al., 1995; . Importantly, (+)-MK-801 did not show ketamine-like long-lasting antidepressant effects in susceptible mice after chronic social defeat stress (CSDS), but it did produce rapid-acting antidepressant effects in CSDS-susceptible mice . Thus, available evidence indicated that NMDAR antagonists could alleviate depression-like behaviors in rodents, which led to several pharmaceutical companies developing NMDAR antagonists as novel antidepressants (Hashimoto, 2019a) .
In a shock-induced depression model, Chaturvedi et al. (1999) reported that the antidepressant effects of (R,S)-ketamine at the dose of 5 and 10 mg/kg respectively significantly increased ambulation and rearing in the open field test and attenuated the increased immobility time in forced swimming test. In a rat learned helplessness (LH) model, Koike et al. (2011) reported that (R,S)-ketamine (10 mg/kg) exerted rapid J o u r n a l P r e -p r o o f 6 antidepressant-like effects that were sustained for at least 72 h after a single dose. In a model of chronic unpredictable mild stress (CUMS), a single dose of (R,S)-ketamine (10 mg/kg) elicited rapid-onset persistent antidepressant effects in rodents (Liu et al., 2016a; Ma et al., 2013; Sun et al., 2016) . Comparable to tropomyosin receptor kinase B (TrkB) agonists and antagonists (7,8-dihydroxyflavone and ANA-12, respectively), it was reported that (R,S)-ketamine showed rapid-acting and longer lasting antidepressant effects in CSDS-susceptible mice . It also showed antidepressant-like effects of (R,S)-ketamine in inflammation-induced depression models (Huang et al., 2019; Lindqvist et al., 2017; Remus and Dantzer, 2016; Yamaguchi et al., 2018; Zhang et al., 2016; Zhang and Hashimoto, 2019a) .
Unfortunately, the potential psychotomimetic and other unwanted side effects of (R,S)-ketamine have also been well-documented in rodents. These include hyperlocomotion, prepulse inhibition (PPI) deficits, conditioned place preference, schizophrenia-like psychotic symptoms, and cognitive deficits (Becker and Grecksch, 2004; Chan et al., 2013; Chang, et al., 2019; Giorgetti et al., 2015; Imre et al., 2006; Lahti et al., 1995; Yang et al., 2015) . These have limited interest in its use in humans.
Brief history of (R,S)-ketamine's antidepressant effects in humans
The discovery of (R,S)-ketamine's antidepressant effects in humans began in the 1970s (Figure 2) . As described in Edward Domino's review article, some PCP (or ketamine) abusers had used (R,S)-ketamine to improve depressive symptoms rapidly when usual antidepressants were not effective (Domino, 2010) . However, he conducted no further study because of concerns that PCP and (R,S)-ketamine were illicit drugs (Domino, 2010) . It was therefore a major advancement when (R,S)-ketamine's antidepressant effects were later acknowledged and the agent was introduced for the treatment of severe depression. Berman et al. (2000) had already demonstrated the rapid-acting and sustained antidepressant effects of (R,S)-ketamine in patients with depression, and these findings were replicated by Zarate et al. (2006) in treatment-resistant patients with major depressive disorder (MDD). Since then, J o u r n a l P r e -p r o o f many studies have confirmed the antidepressant effects of (R,S)-ketamine for treatment-resistant patients with MDD, bipolar disorder, and suicidal ideation (Bobo et al., 2016; Grunebaum et al., 2018; Kishimoto et al., 2016; Murrough et al., 2013; Newport et al., 2015; Singh, et al., 2016b) .
In clinical trials, interventional studies have sought to evaluate the beneficial effects of (R,S)-ketamine. Several randomized single-and double-blind placebo-or drug-controlled studies have replicated the antidepressant effects of (R,S)-ketamine in both MDD and bipolar disorder, even after a single intravenous dose of 0.5 mg/kg (Berman et al., 2000; Zarate et al., 2006) . Another cross-over double-blind study indicated that many patients with treatment-resistant bipolar disorder (71%) showed significant improvements (Diazgranados et al., 2010) . Zarate et al. (2012) also evidenced that depressive symptoms and suicidal ideation improved within 40 minutes of patients with bipolar disorder receiving a single infusion of (R,S)-ketamine.
Furthermore, in a dose-ranging trial of intravenous (R,S)-ketamine, Fava et al. (2018) suggested that there was evidence to support the validity of single dose therapy at either 0.5 mg/kg or 1.0 mg/kg in patients with treatment-resistant depression.
In two midazolam-controlled randomized clinical trials, (R,S)-ketamine caused rapid reductions in suicidal ideation and depressive symptoms within 24 hours (Grunebaum et al., 2018; Murrough et al., 2013) . Moreover, (R,S)-ketamine was shown to have potent anti-suicidal effects in depressed patients with suicidal ideation (Bartoli et al., 2017; Reinstatler and Youssef, 2015; Wilkinson et al., 2018) . These studies indicate that (R,S)-ketamine is a promising antidepressant for the treatment of severe depressed patients with suicide ideation.
Repeated ketamine infusion is important for maintenance therapy in patients
with treatment-resistant depression (Phillips et al., 2019; Strong and Kabbaj, 2018) . In a double-blind, randomized, placebo-controlled study, Singh et al. (2016b) suggested that twice-or thrice-weekly administration of (R,S)-ketamine (0.5 mg/kg) was sufficient to maintain antidepressant efficacy over 15 days in patients with treatment-resistant depression. At present, there is a lack of long-term data on the J o u r n a l P r e -p r o o f 8 long-term safety and efficacy of (R,S)-ketamine for patients with treatment-resistant depression. This is important given the potential for severe side effects.
Antidepressant-like effects of ketamine enantiomers in rodents
(R,S)-ketamine (Ki = 0.53 μM for NMDAR) comprises a racemic mixture of (R)-ketamine (Ki = 1.4 μM for NMDAR) and (S)-ketamine (Ki = 0.30 μM for NMDAR) in equal measure (Figure 1) (Ebert et al., 1997) . In 2014, Zhang et al. (2014) first reported that (R)-ketamine had greater potency and longer lasting antidepressant effects than (S)-ketamine in a neonatal dexamethasone-treated model of depression. In 2015, they further reported that (R)-ketamine had greater potency and longer lasting antidepressant effects than (S)-ketamine in CSDS and LH models of depression . Subsequently, the superiority of (R)-ketamine over (S)-ketamine was reported in rodents Fukumoto et al., 2017; Zanos et al., 2016) . Importantly, (R)-ketamine also has fewer detrimental side effects than either (R,S)-ketamine or (S)-ketamine in rodents and monkey Fukumoto et al., 2017; Hashimoto et al., 2017; Tian et al., 2018a; Yang et al., 2015; Yang et al., 2016) . However, in 2019, Masaki et al. (2019) demonstrated that the functional MRI (fMRI) responses in the brains of conscious rats after a single injection of (S)-ketamine, (R,S)-ketamine, or (+)-MK-801 were different from the fMRI responses after a single injection of (R)-ketamine. Their results indicated that NMDAR inhibition was unlikely to play a role in the pharmacological effects of (R)-ketamine in rat brains (Masaki et al., 2019) .
Antidepressant-like effects of ketamine metabolites in rodents
In 2016, a group led by Dr. Todd Gould (University of Maryland) reported that the metabolism of (R,S)-ketamine to (2R,6R)-hydroxynorketamine (HNK) (Figure 3) was essential for the antidepressant-like effects of the parent compound in rodents (Zanos et al., 2016) . Although (2R,6R)-HNK is a minor metabolite of (R)-ketamine, the dose necessary to achieve antidepressant-like effects was similar to that for (R,S)-ketamine J o u r n a l P r e -p r o o f (Zanos et al., 2016) . Unfortunately, our group was unable to replicate the antidepressant-like effects of (2R,6R)-HNK in rodents with depression-like phenotypes (Chaki, 2018; Chang et al., 2018; Hashimoto and Shirayama, 2018; Shirayama and Hashimoto, 2018; Xiong et al., 2019; Yamaguchi et al., 2018; Zhang et al., 2018c) .
In a study using cytochrome P450 inhibitors, it was shown that metabolism to (2R,6R)-HNK was unnecessary for the antidepressant-like effects of (R)-ketamine, and that (R)-ketamine itself may be responsible for the observed antidepressant-like actions . Clinical study of (2R,6R)-HNK in humans is to be started by the US National Institute of Mental Health. A double-blind randomized study of (R)-ketamine versus (2R,6R)-HNK would be of great interest in depressed patients.
Finally, (S)-ketamine is metabolized to (S)-norketamine (Figure 3) . In 2018, Yang et al. (2018a) reported that (S)-norketamine produced rapid and sustained antidepressant-like effects in a CSDS model. Importantly, unlike to (S)-ketamine, (S)-norketamine did not produce the expected side effects in rodents (Yang et al., 2018a) . Therefore, (S)-norketamine could be an alternative to (S)-ketamine, potentially offering antidepressant efficacy with fewer side effects (Hashimoto, 2019a; Hashimoto, 2019b; Hashimoto and Yang, 2018) . Vollenweider et al. (1997) reported on the psychological state and cerebral glucose metabolism produced after injecting either (S)-ketamine or (R)-ketamine. Although (S)-ketamine produced psychotic reactions, including depersonalization and hallucinations, (R)-ketamine did not produce any psychotic symptoms in the same subjects at the same dose (Vollenweider et al., 1997) . Positron emission tomography showed that (S)-ketamine led to markedly increased glucose utilization in the frontal cortex and thalamus, whereas (R)-ketamine suppressed glucose metabolism in several brain areas (Vollenweider et al., 1997) . Collectively, these results suggested that J o u r n a l P r e -p r o o f (S)-ketamine contributed to the acute side effects of ketamine, whereas (R)-ketamine may be free of these side effects (Hashimoto, 2019a; Zanos et al., 2018) .
Effects of ketamine enantiomers in humans
In the US, Janssen Pharmaceutical developed (S)-ketamine nasal spray for use in treatment-resistant depression. This was based on the results of a double-blind, multicenter, randomized, placebo-controlled trial (Singh, et al., 2016a) in which it was reported that (S)-ketamine (0.2 and 0.40 mg/kg by intravenous infusion) showed a rapid and robust antidepressant effect (within 2 hours) in patients with treatment-resistant depression. The most common treatment-emergent adverse events were headache, nausea, and dissociation (Singh, et al., 2016a) . A recent head-to-head study of (S)-ketamine (0. Interestingly, however, the antidepressant effects of (R,S)-ketamine (0.5 mg/kg) by 7 days after a single injection were more potent than for (S)-ketamine, albeit without statistical significance (P = 0.08) (Correia-Melo et al., 2019) . In contrast, based on the preclinical findings Yang et al., 2018a; Zhang et al., 2014) , it is likely that (R)-ketamine plays a role in the long-lasting antidepressant effects of (R,S)-ketamine. Double-blind, randomized trials of (R)-ketamine versus (S)-ketamine are therefore urgently needed to assess their relative efficacies in patients with depression.
Only two of the five phase III trials performed by Janssen Pharmaceutical showed positive results for (S)-ketamine. Nevertheless, on March 5, 2019, the US FDA approved the use of (S)-ketamine nasal spray (esketamine) for treatment-resistant depression in conjunction with an oral antidepressant (Figure 2) . (Figure 2) (Mahase, 2019) . However, there are many concerns about the efficacy of esketamine nasal spray (Kaur et al., 2019; Turner, 2019; Zimmermann et al., 2020) .
A recent pilot study in Brazil demonstrated that intravenous infusion of (R)-ketamine (0.5 mg/kg for 40-min) elicited rapid-acting and sustained antidepressant actions in treatment-resistant patients with MDD, and that side effects such as dissociation were low (Leal et al, 2020) . At present, a clinical trial of (R)-ketamine by Perception Neuroscience Ltd. is underway for use in depressed patients (Hashimoto, 2019a) .
Mechanisms of ketamine's antidepressant actions

NMDAR inhibition and AMPAR activation
It is widely acknowledged that the rapid antidepressant actions of ketamine occur via blockade of NMDARs located at inhibitory interneurons. This blockade causes the disinhibition of pyramidal cells that result in a burst of glutamatergic transmission (Duman, 2018; Krystal et al., 2019) . Subsequently, activation of the AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) is required for ketamine's antidepressant effects. This was demonstrated by research showing that pretreatment with an AMPAR antagonist blocked ketamine's antidepressant effects in rodents (Maeng et al., 2008) . In addition, the role of AMPAR activation in the antidepressant effects of ketamine and its two enantiomers has been replicated (Autry et al., 2011; Yang et al., 2015) .
Unfortunately, other NMDAR antagonists (e.g., memantine, lanicemine, rapastinel, and AV-101) do not show ketamine-like robust antidepressant actions in patients with depression (Hashimoto, 2019a; Kishimoto et al., 2016; Newport et al., 2015; Sanacora et al., 2017; Yang et al., 2019b; Zarate et al., 2006) . Preclinical data using the two ketamine enantiomers has indicated that NMDAR inhibition may not be central to the antidepressant effects of ketamine in rodents (Hashimoto, 2019a; Yang et al., 2015; 2019b) . Therefore, we must now reconsider the role of NMDAR J o u r n a l P r e -p r o o f inhibition in the antidepressant effects of ketamine and its enantiomers (Yang et al., 2019b ). In addition, there are some questions that remain to be explored although role of NMDAR in ketamine's antidepressant effects is supported by convergent preclinical data. Nonetheless, a full picture of the multiple mechanistic pieces linking ketamine to antidepressant actions is still under experimental scrutiny.
Monoaminergic system
It has long been established that 5-hydroxytyptamine (5-HT) plays a key role in the mechanisms of action of SSRIs and SNRIs. Research also indicates that AMPAR-dependent 5-HT release in the medial prefrontal cortex may be involved in the antidepressant effects of (R,S)-ketamine in rodents without depression-like phenotypes (Chaki and Fukumoto, 2019; Fukumoto et al., 2016) , though it is considered unlikely that 5-HT plays a role in the antidepressant effects of either (R,S)-ketamine or (R)-ketamine in rodents with a depression-like phenotype (Gigliucci et al., 2013; Zhang et al., 2018a) . Therefore, further detailed studies are needed on the role of 5-HT in the antidepressant effects of (R,S)-ketamine and its enantiomers in animals with depression-like phenotypes.
It has also been suggested that the dopamine system plays a role in depression.
A recent study demonstrated that disruption of the dopamine D 1 receptor encoded by the Drd1 in the medial prefrontal cortex blocked the rapid antidepressant effects of (R,S)-ketamine in control mice (Hare et al., 2019) . This finding suggested that activation of dopamine D 1 receptors in the medial prefrontal cortex was necessary for the rapid antidepressant actions of (R,S)-ketamine. By contrast, Li et al. (2015) reported that the dopamine D 1 receptor antagonist SCH-23390 did not block the antidepressant-like effects of (R,S)-ketamine in control mice. It has also been shown that pretreatment with SCH-23390 failed to block the antidepressant effects of (R)-ketamine in CSDS-susceptible mice . A recent study also demonstrated that (S)-ketamine caused a robust increase in dopamine release in the prefrontal cortex compared with (R)-ketamine (Ago et al., 2019) , but that its antidepressant effects were less potent than those of (R)-ketamine in animal models of J o u r n a l P r e -p r o o f depression. Therefore, although it is unlikely that dopamine D 1 receptors play a major role in the antidepressant actions of (R,S)-ketamine or (R)-ketamine, the dopamine system may contribute to some of the observed pharmacological actions .
BDNF-TrkB system
In 2011, Autry et al. (2011) demonstrated that the rapid-acting antidepressant effects of (R,S)-ketamine were dependent on the rapid synthesis of brain-derived neurotrophic factor (BDNF); this was based on the finding that (R,S)-ketamine did not cause antidepressant-like effects in inducible Bdnf-knockout mice. Subsequent studies have replicated the role of the BDNF-TrkB cascade in the antidepressant effects of (R,S)-ketamine (Yang et al., 2013; Zhou et al., 2014) . The TrkB inhibitor ANA-12 has also been shown to block the rapid and long-lasting antidepressant effects of (R)-ketamine and (S)-ketamine in CSDS-susceptible mice .
Regulation of glutamate transporter 1 on astrocytes, through the activation of TrkB, also appears to play a role in the beneficial effects of (R,S)-ketamine on behavioral abnormalities and in the morphological changes seen in the hippocampi of rats exposed to CUMS (Liu et al., 2016a) . Collectively, it is likely that prolonged activation of the BDNF-TrkB cascade in the prefrontal cortex and hippocampus is responsible for the long-lasting antidepressant effects of (R,S)-ketamine and its enantiomers.
mTORC1 and ERK
In 2010, Dr. Ronald Duman (Yale University) and colleagues demonstrated that rapamycin, an mTOR inhibitor, blocked the antidepressant-like effects of (R,S)-ketamine in rodents (Li et al., 2010) . By contrast, Autry et al. (2011) later showed that the level of phosphorylated mTOR was not altered in the hippocampi of control and Bdnf-knockout mice after injecting (R,S)-ketamine. The antidepressant-like effects of (R,S)-ketamine were not affected by rapamycin in wild-type mice. Furthermore, it was shown that (R,S)-ketamine did not alter the levels of phosphorylated mTOR in the hippocampi and prefrontal cortexes of mice, but that J o u r n a l P r e -p r o o f the levels of phosphorylated eukaryotic elongation factor 2 and BDNF were significantly increased in the hippocampi (Zanos et al., 2016) . Interestingly, a CSDS model indicated that mTORC1 plays a major role in the antidepressant effects of (S)-ketamine, but not in those of (R)-ketamine, (Yang et al., 2018b) . Instead, the antidepressant effects of (R)-ketamine may be mediated by ERK activation, based on evidence that pretreatment with SL327 (an ERK inhibitor) inhibited its antidepressant effects (Yang et al., 2018b) .
A recent randomized, placebo-controlled clinical study demonstrated that rapamycin did not alter the acute effects of (R,S)-ketamine in treatment-resistant patients with depression, but that combination therapy led to prolonged antidepressant effects (Abdallah et al., 2018) . As such, the role of mTORC1 in the antidepressant effect of (R,S)-ketamine has not been confirmed in treatment-resistant patients with depression. Further investigation using a larger sample should help to confirm the role of mTORC1 in the antidepressant effects of (R,S)-ketamine and its enantiomers in clinically depressed patients.
Low-voltage-sensitive T-type calcium channel
In 2018, a group of Dr. Hailan Hu (Zhejiang University) demonstrated that blockade of NMDAR-dependent bursting activity in the lateral habenula was induced by (R,S)-ketamine. Further, they showed that this lateral habenula bursting promoted rapid-acting antidepressant effects in rodents and that it required both NMDARs and low-voltage-sensitive T-type calcium channels (Yang et al., 2018c) . Giving ethosuximide (200 mg/kg), a T-type calcium channel inhibitor, resulted in rapid antidepressant effects in rodents (Yang et al., 2018c) . However, giving ethosuximide (100, 200, 400 mg/kg) did not produce any antidepressant actions in CSDS-susceptible mice, whereas (R)-ketamine did, in the same model (Tian et al., 2018b) . A recent double-blind, placebo-controlled study demonstrated that ethosuximide did not produce antidepressant actions in medication-free patients with depression (Zhang et al., 2020a) . At present, a randomized clinical trial is underway at Zhejiang University in China to assess the effects of ethosuximide in treatment-resistant patients with depression .
Opioid system
It is well known that ketamine interacts with opioid receptors, with (S)-ketamine binding to mu and kappa receptors being 2-to 4-fold stronger than that of (R)-ketamine (Domino, 2010; Hirota and Lambert, 1996) . Pretreatment with the opiate receptor antagonist naltrexone (50 mg) significantly blocked the antidepressant and anti-suicidal effects of (R,S)-ketamine in treatment-resistant patients with depression, suggesting that activation of the opioid system was necessary to produce the rapid-acting antidepressant effects of (R,S)-ketamine (Williams et al., 2019; Williams et al., 2018) . Other research has shown that pretreatment with naltrexone did not alter the antidepressant effects of (R,S)-ketamine in depressed patients with alcohol use disorder (Yoon et al., 2019) . Furthermore, (R,S)-ketamine still produced antidepressant effects in patients concurrently receiving a high-affinity mu opioid receptor agonists (i.e., buprenorphine, methadone, or naltrexone) (Marton et al., 2019) .
Thus, the role of the opioid system in the antidepressant effects of (R,S)-ketamine remains controversial in humans.
In CSDS and inflammation-induced models of depression, naltrexone pretreatment did not block the antidepressant-like effects of (R,S)-ketamine, suggesting that the opioid system may not facilitate the antidepressant-like effects of (R,S)-ketamine (Zhang and Hashimoto, 2019a) . However, a recent study showed that NMDAR and opioid receptors were required for (R,S)-ketamine to reduce the depression-like and lateral habenula hyperactive cellular phenotypes in congenital LH rats (Klein et al., 2020) . Both the behavioral and cellular effects of (R,S)-ketamine were blocked by naltrexone in congenital LH rats (Klein et al., 2020) . The authors concluded that (R,S)-ketamine likely does not act as an opiate at antidepressant doses, J o u r n a l P r e -p r o o f with its cellular and behavioral effects instead primarily mediated through the NMDAR (Klein et al., 2020) . Further study with each ketamine enantiomer is needed to confirm the role of the opioid system in the antidepressant actions of (R,S)-ketamine.
Transforming growth factor β1 system
The molecular mechanisms underpinning (R)-ketamine's antidepressant effects remain unclear, especially compared with our understanding of (S)-ketamine.
However, based on RNA sequencing analysis, we demonstrated that transforming growth factor (TGF)-β1 in the microglia plays a role in the antidepressant effects of (R)-ketamine (Zhang et al., 2020b) . Of even greater interest, TGF-β1 was shown to elicit rapid-acting and long-lasting antidepressant effects in CSDS, LH, and inflammation models (Zhang et al., 2020b) . As such, it is likely that TGF-β1 could be a novel therapeutic target for depression.
Brain-gut-microbiota axis
Multiple lines of evidence suggest a possible role of the brain-gut-microbiota axis in the stress-induced depression-like phenotype and in the antidepressant-like effects of certain compounds (Carlessi et al., 2019; Wang et al., 2020; Yang et al., 2017a; Yang et al., 2019a; Zhang et al., 2017; Zhang et al., 2019) . (R,S)-ketamine is shown to improve abnormal composition of gut microbiota in rodents with depression-like phenotype (Huang et al., 2018) . Furthermore, (R)-ketamine ameliorated abnormal composition of gut microbiota in the CSDS susceptible mice (Yang et al., 2017b; Qu et al., 2017) . Taken together, the brain-gut-microbiota axis may, in part, play a role in the antidepressant actions of (R)-ketamine [or (R,S)-ketamine], although further studies are needed.
Concluding remarks
The discovery that (R,S)-ketamine had robust antidepressant actions in depressed patients was certainly serendipitous , and has so far led to the esketamine nasal spray being approved for use in treatment-resistant depression in Journal Pre-proof J o u r n a l P r e -p r o o f 17 both the US and Europe, despite several concerns about its efficacy and side effects.
By contrast, there are no therapeutic options for (R)-ketamine, although clinical research is underway in humans. From the preclinical and clinical findings, it seems that safety profile of (R)-ketamine in humans is better than (R,S)-ketamine and (S)-ketamine (Hashimoto, 2019a; 2019b; 2020) . This is of great importance because there is accumulating preclinical data to show that (R)-ketamine has greater antidepressant potency and elicits longer lasting effects than either (R,S)-ketamine or (S)-ketamine. Collectively, existing data indicate that (R)-ketamine could be a safer antidepressant, necessitating that the research community conduct double-blind randomized study comparing (R)-ketamine with (S)-ketamine in depressed patients.
As mentioned, non-ketamine NMDAR antagonists fail to produce robust ketamine-like antidepressant effects in patients with depression (Hashimoto, 2019a ), suggesting that mechanisms other than NMDAR inhibition play a role in the antidepressant effects of (R,S)-ketamine (Hashimoto, 2019a; Yang et al., 2019b) .
Further detailed study is therefore needed to identify the primary target of (R,S)-ketamine's antidepressant actions. Ki values for NMDAR are presented in parenthesis (Ebert et al., 1997) . Ki values for NMDAR are presented in parenthesis (Ebert et al., 1997; Zanos et al., 2016) . 
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